Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus. by Jit, Mark & Brisson, Marc
Jit, M; Brisson, M (2018) Potential lives saved in 73 countries by
adopting multi-cohort vaccination of 9-14 year old girls against human
papillomavirus. International journal of cancer Journal international
du cancer. ISSN 0020-7136 DOI: https://doi.org/10.1002/ijc.31321
Downloaded from: http://researchonline.lshtm.ac.uk/4646687/
DOI: 10.1002/ijc.31321
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differenĐĞƐďĞƚǁĞĞŶƚŚŝƐǀĞƌƐŝŽŶĂŶĚƚŚĞsĞƌƐŝŽŶŽĨZĞĐŽƌĚ͘WůĞĂƐĞĐŝƚĞƚŚŝƐĂƌƚŝĐůĞĂƐĂŶ͚ĐĐĞƉƚĞĚ
ƌƚŝĐůĞ͕͛ĚŽŝ͗ϭϬ͘ϭϬϬϮͬŝũĐ͘ϯϭϯϮϭ 
 This article is protected by copyright. All rights reserved. 
Short title 
Lives saved by multi-cohort HPV vaccination 
Long title 
Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14 year old 
girls against human papillomavirus 
Authors 
Mark Jit 1,2 and Marc Brisson3 
1London School of Hygiene & Tropical Medicine, 2Public Health England, 3Centre de 
recherche du CHU de Québec, Université Laval 
 
Corresponding author information 
 
Mark Jit 
Department of Infectious Disease Epidemiology 
Faculty of Epidemiology and Population Health 
London School of Hygiene & Tropical Medicine 
Keppel Street 
London WC1E 7HT 
Telephone: +44 (0)2079272852 
E-mail: mark.jit@lshtm.ac.uk 
 
Key words 
 
Human papillomavirus, vaccination, low and middle income countries, mathematical 
modelling 

	




 	

 Abbreviations used 
DoV Decade of Vaccines 
HPV human papillomavirus 
LMICs low- and middle-income countries 
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Novelty and impact 
 
Most low- and middle-income countries have introduced routine human papillomavirus 
vaccination for just a single age-cohort of girls each year. In 2016, Gavi, the Vaccine 
Alliance opened a funding window for countries to vaccinate multiple age-cohorts of girls 
aged 9-14 years in the year of routine vaccine introduction. The authors show that multi-
cohort vaccination in 73 low and lower-middle income countries could increase the lives 
saved by vaccination by 30-40%, and potentially be cost-effective. 


	




 Abstract 
Up to 2016, low- and middle-income countries mostly introduced routine human 
papillomavirus (HPV) vaccination for just a single age-cohort of girls each year. However, 
KLJKLQFRPHFRXQWULHVKDYHUHSRUWHGODUJHUHGXFWLRQVLQ+39SUHYDOHQFHIROORZLQJ³FDWFK-
XS´YDFFLQDWLRQRIPXOWLSOHDJH-cohorts in the year of HPV vaccine introduction. We used the 
mathematical model PRIME to project the incremental impact of vaccinating 10-14-year old 
girls compared to routine HPV vaccination only in the same year that routine vaccination is 
expected to be introduced for 9-year old girls across 73 low and lower-middle income 
countries. Adding multiple age-cohort vaccination could increase the number of cervical 
cancer deaths averted by vaccine introductions in 2015-2030 by 30-40% or an additional 
1.23-1.79 million over the lifetime of the vaccinated cohorts. The number of girls needed to 
vaccinate to prevent one death is 101 in the most pessimistic scenario, which is only slightly 
greater than that for routine vaccination of 9-year old girls (87). These results hold even when 
assuming that girls who have sexually debuted do not benefit from vaccination. Results 
suggest that multiple age-cohort vaccination of 9-14-year old girls could accelerate HPV 
vaccine impact and be cost-effective. 
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 Introduction 
Human papillomavirus (HPV) vaccination protects vaccinees against HPV infection, a 
necessary cause of cervical cancer. Cervical cancer kills 266,000 women every year, with 
82% of them in low- and middle-income countries (LMICs).1 Yet up to October 2014, only 
1% of the 118 million females vaccinated against HPV were from LMICs.2 
 
HPV vaccine introduction in most high-income countries was accompanied with multiple 
age-cohort (multi-cohort) oU³FDWFK-XS´vaccination during which females older than the age 
of routine vaccination were offered vaccination, with an upper limit of around 15-26 years 
depending on the country.2 These countries have already seen large reductions in HPV 
prevalence and (for countries using the quadrivalent vaccine) anogenital warts incidence 
across a wide age range.3 Rapid reduction in anogenital warts incidence following HPV 
vaccination in countries like Australia has been largely attributed to catch-up vaccination.4 
 
In contrast, LMICs have mostly introduced routine HPV vaccination for just a single age-
cohort of girls each year. Until 2016, the World Health Organization (WHO) recommended 
prioritizing routine vaccination of 9-13 year old girls without any mention of multi-cohort 
vaccination.5 Funding for vaccination from Gavi, the Vaccine Alliance, only covered 
vaccination of a single age-cohort per year. 
 
,Q2FWREHUWKH:RUOG+HDOWK2UJDQL]DWLRQ¶V6WUDWHJLFAdvisory Group of Experts on 
Immunization revised its position to recommend delivering vaccination to multiple age-
cohorts of girls aged 9-14 years.6 Shortly afterwards, Gavi opened a funding envelope to 
allow countries to vaccinate multiple age-cohorts of girls aged 9-14 years in the year of HPV 
vaccine introduction.7 Expanding multi-cohort vaccination to LMICs offers the opportunity 
to accelerate the slow pace of HPV vaccination in these settings. However, there are concerns 
that the impact of multi-cohort vaccination will be curtailed if girls are likely to be infected 
with vaccine-type HPV prior to being vaccinated, since HPV vaccines do not affect prevalent 
infections at the time of vaccination.  
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 To address these concerns, we conducted data analysis and modelling work to project the 
potential incremental impact of multi-cohort vaccination in 73 Decade of Vaccines (DoV) 
countries projected to introduce HPV vaccination in 2015-2030. DoV countries are those that 
the Global Vaccine Action Plan for 2011-2020 focuses on, consisting of countries classified 
as low or lower-middle income by the World Bank in 2011.8 These analyses were used to 
inform the decisions by WHO and Gavi to support multi-cohort vaccination. 
 
Methods 
 
Model overview 
 
We estimated the impact of different HPV vaccination strategies in DoV countries using the 
Papillomavirus Rapid Interface for Modelling and Economics (PRIME). PRIME is a static, 
proportional impact model of HPV vaccination that was developed in collaboration with 
WHO to estimate the impact and cost-effectiveness of introducing HPV vaccination in 
LMICs. It is also used to inform vaccine impact estimates used by Gavi and the Bill & 
Melinda Gates Foundation.  
 
The model equations and inputs have been extensively described elsewhere9 and the Excel-
based code with accompanying documentation is freely available online 
(www.primetool.org). Herd (indirect) effects and cross-protection against non-vaccine HPV 
types are not considered, so impact estimates for routine vaccination should be regarded as 
conservative. However, previous validation exercises suggest that PRIME gives comparable 
cost-effectiveness estimates for routine female-only vaccination to transmission dynamic 
models in the literature. 9 Since PRIME was originally designed to measure the impact of 
vaccinating girls prior to sexual debut, for this exercise we adjusted the original model to take 
into account that vaccinating up to age 14 may involve giving vaccines to some girls who are 
already HPV infected (see below for details). 
 
Vaccine effectiveness 
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 We assume that vaccinating girls prior to infection with HPV types 16 and 18 fully protects 
them from developing cervical cancer caused by HPV 16 and 18, in accordance with vaccine 
trials.10 However, the proportion of girls aged 9-14 years who are HPV 16/18 infected is not 
available for most DoV countries. As a proxy for HPV infection, we examined sexual 
behaviour in the same age group. We explored two scenarios: a pessimistic scenario in which 
vaccination would give no protection at all to girls who had sexually debuted, and an 
optimistic scenario in which vaccination would still fully protect these girls. 
 
Data sources 
 
Data sources for model parameters are summarised in Supplemental Appendix 4. Of 94 DoV 
countries, we excluded 15 not projected to introduce HPV vaccination in 2015-2030 and 6 
lacking both sexual activity and World Development Indicator information. For the 
remaining 73 countries (see Supplemental Appendix 3), input parameters used in previous 
publications9 were used apart from the exceptions below: 
1) Country population. United Nations World Population Prospects 2015 figures were 
obtained for number of females in the 5-9 and 10-14-year old age groups in 2015-2030.  
2) Vaccine coverage. HPV vaccine introduction years and subsequent vaccine coverage were 
based on Gavi¶V Strategic Demand Forecast version 12, released in 2015.11 This forecast 
UHSUHVHQWV*DYL¶VEHVWHVWLPDWHVDERXWFRXQWULHV¶H[SHFWHGWLPHRILQWURGXFWLRQDQG
corresponding vaccine coverage, but does not constitute any commitment or obligation by the 
countries. Many countries are forecast to have an initial period of coverage scale-up, with low 
vaccine coverage in the year of introduction that gradually increases to a higher projected 
level of coverage several years after vaccine introduction. Vaccine coverage in the year of 
introduction ranges from 6% - 79% (average by country 63%) and rises to reach a maximum 
of 50% - 99% (average by country 91%) (see Table 1). We also considered a low-coverage 
scenario in which vaccine coverage of the relevant age-cohort never exceeds 45%, the 
coverage of 2 doses among United States females in 2015-16.12 
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 3) Age at sexual debut. Demographic and Health Survey (DHS) data report the proportion of 
females who have become sexually active by age 15, 18, 21 and 25 years. DHS data were 
available for 53 out of 73 countries comprising 84% of the 9-year old female age-cohort (see 
Supplemental Appendix 3). 
 
Extrapolation of sexual activity data 
 
Data are not available for sexual activity before age 15 years. Hence, we fitted two functions 
(a logit function and a gamma cumulative distribution function) to data at the four ages with 
data, giving equal weight to each point i.e. we chose the values of a and b to minimise the 
sum of squared residuals between the proportion of sexually active females at age x years and 
the function f(x) = 1/(1+e-a(x+b)) (logit) or f(x) = 1/*(a) J(a,bx) (gamma). The best fitting of 
the two models (based on the deviance) was used to extrapolate sexual debut in females 
younger than 15 years.  
 
We validated our model using sexual debut data in 12-30 year olds from Benin13, three cities 
in Kartanaka, India (Mysore, Bellary and Belgaum)14, the United States15, Canada16 and the 
United Kingdom17. We fit the gamma model to data at age 15, 18, 20 and 25 years only, and 
examined whether the model was able to reproduce data at the other ages well. 
 
Of the 73 countries we examined, 20 had no relevant DHS sexual activity data. These were 
matched to countries with such data in a three-step process based on similarity of other 
variables: (i) using linear regression to select predictors of female sexual activity at age 15 
years from a basket of indicators in the 53 countries with data, (ii) using an clustering 
algorithm to partition 73 countries into eight clusters based on similarities in the predictors of 
sexual activity, and (iii) matching countries without relevant data to the same-cluster country 
with the highest proportion of sexually active females at age 15 years. Technical details of 
these procedures are given in Supplemental Appendix 2. 
 
Vaccine strategies and outcomes 
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 We compared two scenarios: (i) the current Gavi scenario, in which only 9-year old girls are 
offered vaccination, and (ii) a multi-cohort vaccination scenario, in which girls aged 9-14 
years are offered vaccination in the first year of vaccine introduction. In subsequent years, 
only 9-year old girls are vaccinated. We assumed that a multi-cohort campaign would enable 
first year coverage in all catch-up age groups to be equal to the highest routine coverage 
attained. An alternative scenario at 75% of the highest routine coverage was also explored. 
Vaccinations expected to take place in the period 2015-2030 were considered. 
The primary outcome is the number of deaths due to cervical cancer prevented by vaccinating 
these cohorts over the lifetime of the vaccinated cohorts. Results are presented aggregated 
over (i) the year in which vaccination is delivered, and (ii) the year in which the outcome 
(averted deaths) occurred. 
As a secondary outcome, we calculated the number needed to vaccinate to prevent one 
cervical cancer-related death, a common metric used to describe the efficiency of HPV and 
other vaccines.18 This was defined as the ratio of the number of fully vaccinated girls divided 
by cervical cancer deaths prevented over the lifetime of the vaccinated girls. 
 
Results 
 
The proportion of girls reported in DHS to be sexually active at age 15 ranges from 0.3% 
(Turkmenistan, Ukraine) to 35.0% (Chad), with a mean proportion of 14.4% averaged over 
countries. The gamma model fit DHS data on sexual activity better than a logit model, with 
deviance of 0.15 (gamma) vs. 0.46 (logit) (Supplemental Appendix 1). The gamma model 
was also able to reproduce sexual activity data on 12-30-year olds in Benin, India, the United 
States, Canada and the United Kingdom (Figure 1). 
 
Multi-cohort vaccination accelerates the impact of HPV vaccination on cervical cancer. If 
routine vaccine introductions in 2015-2030 are accompanied with multi-cohort vaccination 
for 10-14-year old girls in the same year, then an additional 1.23-1.79 million deaths would 
be averted over the lifetime of the vaccinated cohorts (see Table 2 and Figure 2). This 
represents a 30-40% proportional increase in deaths prevented compared to vaccinating 9-
 year old girls alone. This assumes that sexually active vaccinees are not protected; the 
uncertainty range represents differences between achieving 75% and 100% of maximum 
routine coverage. Multi-cohort vaccination also accelerates the health benefits from 
vaccination, as can be seen in Figure 1(c) where the deaths averted from vaccinating 10-14-
year girls occurs earlier than deaths averted from vaccinating 9-year routine cohorts. The 
number of 10-14-year old girls that need to be vaccinated to prevent one cancer death in 
multi-cohort vaccination is 101, compared to 87 for routine vaccination at 9 years. If a more 
optimistic scenario is assumed where sexually active girls are still protected by vaccination, 
then the number needed to vaccinate to prevent one cancer death in multi-cohort vaccination 
is 93. The results of the two scenarios are similar, indicating that there is limited sexual 
activity below age 15. 
Vaccination at age 10-14 is almost as efficient as vaccination at age 9. If single-cohort HPV 
vaccination was introduced at the timing predicted by Gavi to females aged 9, 10, 11, 12, 13 
or 14 years then the number needed to vaccinate to prevent one cervical cancer death would 
be 87, 87, 87, 90, 98 or 111 respectively. 
In the low-coverage scenario, the number of lives incrementally saved by multi-cohort 
vaccination of 10-14-year olds halves to 0.63-0.91 million, but the number needed to 
vaccinate to prevent a death is largely unchanged (Supplemental Appendix 5). 
Discussion 
Our results show that multi-cohort vaccination of 10-14-year old girls when routine HPV 
vaccination for 9-year old girls is introduced could substantially increase the impact of 
vaccination by accelerating reduction in cervical cancer deaths. Up to 2016, the focus in DoV 
countries has been on delivering HPV vaccines to girls at the lower end of the age range for 
HPV vaccine indications (i.e. close to 9 years old). This is because vaccine effectiveness is 
reduced if vaccinees are HPV infected before vaccination. 

	




 The number of girls that need to be vaccinated to prevent a cancer death in multi-cohort 
vaccination is only slightly greater than that for routine vaccination. Since all females under 
15 years are recommended to receive two doses of vaccine, if each 10-14-year old can be 
given a vaccine dose at the same cost as a 9-year old, then multi-cohort vaccination would 
have a similar cost-effectiveness profile as routine vaccination. Since routine vaccination is 
cost-effective in almost all countries in the world,9 there is a strong case that 10-14 year old 
females should be entitled to the same benefits from vaccination as those aged 9 years.  
 
This is the first paper to look at the impact of the new WHO recommendations on multi-
cohort vaccination in 10-14-year old females in DoV countries. Most modelling papers 
looking at the impact of HPV catch-up campaigns have been limited to high-income 
countries.1920 Most such papers found catch-up campaigns to be cost-effective when 
compared to routine vaccination alone, although the upper age limit for cost-effectiveness 
ranged between studies from 15 years to 24 years. None of the 25 articles in a recent 
systematic review of HPV vaccine cost-effectiveness studies in low- and middle-income 
countries21 analysed multi-cohort vaccination. To our knowledge only two papers (neither of 
them in the review) have looked at multi-cohort HPV vaccination in LMICs. One paper22 
found that catch-up for 12-15 year old girls in Poland and Guinea brought forward reductions 
in HPV infection by up to 5 years earlier, but did not look at the impact on cancer. A second 
paper23 found that very extensive catch-up campaigns (11-26 years and 11-75 years) 
increased WKHLPSDFWRIIHPDOH+39YDFFLQDWLRQLQWKH/DR3HRSOH¶V'HPRFUDWLF5HSXEOLF 
 
Our analysis used PRIME, a static model that projects vaccine impact without requiring 
detailed information about sexual mixing and intermediate disease markers such as HPV 
prevalence or screening outcomes. It does not capture indirect (herd) effects on unvaccinated 
females as a result of reduced transmission in the population. However, the error in ignoring 
herd effects is small when evaluating vaccinating young females at coverage close to 100%. 
Given that 80/87 (92%) of the countries expected to introduce HPV vaccination between 
2015-2030 are projected to achieve coverage of 80% or greater, the estimates using PRIME 
are likely to be satisfactory. Furthermore, transmission dynamic models have found that the 
benefits of vaccinating females in multi-cohort campaigns are similar to vaccinating routine 
cohorts as long as the females are under around 15 years old. However, the precise magnitude 
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 of the herd effects depends on type-specific transmission and clearance rates as well as the 
characteristics of the population in each country. 
Coverage assumptions were based on Gavi projections of future vaccine demand. However, 
not many countries have achieved the high levels of coverage that Gavi projects. 
Furthermore, in several countries vaccine coverage has fallen following (unfounded) safety 
concerns.24 In a sensitivity analysis with coverage assumptions closer to those currently being 
achieved in the United States, the impact of multi-cohort vaccination of 10-14-year olds 
halves (Supplemental Appendix 5). Herd effects may be greater at lower levels of coverage, 
so this may partly mitigate the reduction. On the other hand, if 2 doses of HPV vaccines do 
not provide long-lasting protection as we have assumed, then the impact of coverage declines 
will be greater. Extending vaccination to males may allow programmes to achieve resilience 
against short-term declines in coverage.25 
 
Another simplification is that we assumed that any girl who has sexually debuted is HPV 
16/18 infected and does not benefit from HPV vaccination at all. This assumption allows us 
to adjust the differences in HPV exposure using only data on the onset of sexual debut across 
the countries. However, the proportion of 15-year olds who have sexually debuted does not 
exceed 35% in any DoV country with relevant DHS data, and is substantially lower in most 
countries. Hence even when making this extremely pessimistic assumption, the effectiveness 
of vaccination at age 14 is only slightly lower than at age 9. For comparison, although 18% of 
British females are sexually active at age 15,17 fewer than 5% are seropositive for HPV 16 or 
18 at that age.26 Similarly, in the PATRICIA trials of the bivalent HPV vaccine, 96% of 
participants were sexually active, but only 19% and 13% were either antibody or DNA 
positive to HPV 16 and HPV 18 respectively.27 
 
All these model simplifications lead to our analysis underestimating the benefit of 
vaccination i.e. the benefit of multi-cohort vaccination may be even greater than we show 
here. Hence we have followed World Health Organization guidelines, which allow the use of 
a conservative static model (that underestimates vaccine impact) provided that this still 
produces outcomes that are favourable to vaccination.28 
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 A further limitation is that we assume (like most published models) that cervical cancer 
incidence will not change in the future. Future incidence depends on trends in sexual 
behaviour, screening uptake, HIV prevalence, all-cause mortality and other factors. However, 
long-term cervical cancer incidence projections taking all relevant factors into account have 
never been published. 
While the impact of multi-cohort vaccination is potentially large, there are still delivery 
questions that need to be addressed. First, multi-cohort vaccination will require much larger 
HPV vaccine stocks, particularly in 2018 when several large countries are predicted to 
introduce HPV vaccination. Second, female school enrolment in many countries drops after 
primary school. Hence school-based vaccination may have lower coverage in multi-cohort 
age groups compared to routine cohorts. Furthermore, DHS data indicates an association 
between being sexually active by age 15 and not having secondary or post-secondary 
education at the country level (data not shown). This may suggest that out-of-school girls are 
more likely to be at risk of HPV infection and disease. Hence vaccinating girls at secondary 
school age may require strategies that are able to reach out-of-school girls to have maximal 
impact. 
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 Table 2. Number of fully vaccinated girls and lives saved by vaccination during 2015 ± 2030 
under different coverage and vaccine protection scenarios explored. The proportion of girls 
assumed to be sexually active was estimated by extrapolating the DHS data on the proportion 
of females who have become sexually active by age 15, 18, 21 and 25 years (proportion 
sexually active at age 15 years ranged across countries from 0.3% to 35.0%). 
 
Total Incremental to routine only 
Scenario Fully 
vaccinated 
girls (m) 
Lives 
saved 
(m) 
Number 
needed to 
vaccinate 
Fully 
vaccinated 
girls (m) 
Lives 
saved 
(m) 
Number 
needed 
to 
vaccinate 
Routine at 9y 366 4.2 87 - - - 
Pessimistic scenario: sexually active vaccinees are not protected 
+ Catch-up 9-
14y at 100% 
of routine 
coverage 
532 5.8 91 166 1.65 101 
+ Catch-up 9-
14y at 75% of  
routine 
coverage 
491 5.4 91 124 1.23 101 
Optimistic scenario: Sexually active vaccinees are protected 
+ Catch-up 9-
14y at 100% 
of routine 
coverage 
532 6.0 89 166 1.79 93 
+ Catch-up 9-
14y at 75% of  
routine 
coverage 
491 5.5 89 124 1.34 93 
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 Figure legends 
Figure 1. Sexual activity data from seven settings and corresponding best fitting gamma 
model when fit to data at age 15, 18, 20, 22 and 25 years only. Prediction intervals are 
generated using Monte Carlo sampling from the variance-covariance matrix of the regression 
coefficients. 
Figure 2. Number of (a) fully vaccinated girls, (b) cancer deaths prevented by year of 
vaccination and (c) cancer deaths prevented by year that death occurs, when vaccinating over 
the SDF v. 12 time period (2015 ± 2030) with routine vaccination only compared to multi-
cohort vaccination at 100% routine coverage. 
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